Qube Research & Technologies (QRT)
DYN icon

Qube Research & Technologies (QRT)’s Dyne Therapeutics DYN Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-253,153
Closed -$4.59M – 3612
2026
Q1 		$4.59M Sell
253,153
-159,287
-39% -$2.75M 0.01% 1706
2025
Q4 		$8.07M Sell
412,440
-417,329
-50% -$7.9M 0.01% 1480
2025
Q3 		$10.5M Buy
829,769
+37,782
+5% +$431K 0.01% 1295
2025
Q2 		$7.54M Buy
791,987
+111,151
+16% +$1.22M 0.01% 1466
2025
Q1 		$7.12M Buy
680,836
+413,459
+155% +$5.91M 0.01% 1339
2024
Q4 		$6.3M Buy
267,377
+244,211
+1,054% +$7.22M 0.01% 1362
2024
Q3 		$832K Buy
+23,166
New +$922K ﹤0.01% 2096
2024
Q2 		– Sell
-100,656
Closed -$2.86M – 4019
2024
Q1 		$2.86M Buy
100,656
+47,312
+89% +$1.07M ﹤0.01% 1558
2023
Q4 		$709K Buy
+53,344
New +$521K ﹤0.01% 2104
2023
Q2 		– Sell
-17,726
Closed -$204K – 2538
2023
Q1 		$204K Buy
+17,726
New +$230K ﹤0.01% 1933

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Qube Research & Technologies (QRT)'s DYN Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of Dyne Therapeutics (DYN) in Q2 2026, closing a stake of 253,153 shares — an estimated $4.59M sold.

Qube Research & Technologies (QRT) first reported a position in DYN in Q1 2023 and held it in 10 quarters. The position peaked at $10.5M in Q3 2025. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Qube Research & Technologies (QRT) reported no remaining Dyne Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 253,153 Dyne Therapeutics shares in Q2 2026, an estimated $4.59M.
  • Qube Research & Technologies (QRT) first reported a position in Dyne Therapeutics in Q1 2023 and held it in 10 quarters.
  • Qube Research & Technologies (QRT)'s Dyne Therapeutics position peaked at $10.5M in Q3 2025.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.